• Edesa Biotech to continue global Covid-19 drug trial pharmaceutical-technology
    June 22, 2021
    Edesa Biotech is set to continue Phase II/III clinical study of its drug candidate, EB05, to treat patients hospitalised with Covid-19 on receiving an independent Data and Safety Monitoring Board’s (DSMB) recommendation.
PharmaSources Customer Service